Cite
HARVARD Citation
Kijak, G. et al. (n.d.). 1160. Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVID-19 in Adults. Open forum infectious diseases. p. . [Online].